Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.50 Average Price Target from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has received an average recommendation of "Buy" from the ten brokerages that are currently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $62.50.

A number of brokerages have commented on JSPR. UBS Group started coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price target for the company. JMP Securities reaffirmed a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating on the stock in a research note on Thursday, January 9th. Finally, HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, March 11th.

Institutional Trading of Jasper Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its position in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after acquiring an additional 1,698 shares in the last quarter. MetLife Investment Management LLC increased its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock worth $129,000 after buying an additional 3,873 shares during the period. Wells Fargo & Company MN lifted its holdings in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after buying an additional 3,828 shares in the last quarter. EntryPoint Capital LLC purchased a new position in Jasper Therapeutics in the 4th quarter valued at approximately $223,000. Finally, Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics in the third quarter worth $251,000. Institutional investors and hedge funds own 79.85% of the company's stock.

Remove Ads

Jasper Therapeutics Stock Up 2.9 %

Shares of NASDAQ JSPR traded up $0.16 during mid-day trading on Monday, reaching $5.65. 201,608 shares of the company were exchanged, compared to its average volume of 266,391. Jasper Therapeutics has a 1 year low of $4.55 and a 1 year high of $31.01. The stock has a market cap of $84.87 million, a price-to-earnings ratio of -1.19 and a beta of 2.23. The firm has a 50-day moving average of $6.14 and a 200 day moving average of $15.68.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, equities analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.